Background-Transcaval access may enable fully percutaneous transcatheter aortic valve replacement (TAVR) without the hazards and discomfort of transthoracic (transapical or transaortic) access.
Introduction
Transcatheter aortic valve implantation (TAVR) avoids the morbidity and mortality of surgical aortic valve replacement in high and intermediate risk patients (1) (2) (3) (4) (5) (6) . Transthoracic (transapical and transaortic) access is inferior compared with femoral-artery access (6) , perhaps in part because of the clinical features precluding femoral artery access. Discomfort and morbidity are more pronounced from transthoracic access for TAVR, probably because of invasiveness and pulmonary insults. An alternative transfemoral access approach to TAVR might be desirable in these patients to reduce the hazards and discomfort of transthoracic access and because of the superior operator ergonomics.
We developed a technique of transfemoral venous access for retrograde TAVR by entering the abdominal aorta through the adjoining inferior vena cava, which is now called transcaval access (7) (Central Illustration). Animals tolerate the resulting acute aorto-caval fistula even without repair, because the retroperitoneal space appears to pressurize and cause aortic blood to return immediately through the corresponding hole in the vena cava ( Figure 2 ). Patients tolerate transcaval access after implanting nitinol cardiac occluders to close the aortic port. Transcaval access and closure was uniformly successful in the first 19 patients, all of whom had no good TAVR access options (8) .
We have refined the technique of transcaval access and closure (9) and tested the early multicenter experience in a single-arm prospective Investigational Device Exemption trial in patients deemed to have high or prohibitive risk of complications from transthoracic access for TAVR. This paper describes 30-day outcomes in 100 patients.
Methods

Patients and study design
The study evaluated success and complications of transcaval TAVR access and closure with a nitinol cardiac occluder device. It was designed as a prospective open-label multi-center single-arm study with on-site monitoring, independent endpoint adjudication, and central core laboratory analysis of follow-up images (NCT02280824).
Subjects were eligible to participate if (1) they had severe symptomatic native aortic valve stenosis or bioprosthetic aortic valve failure for which TAVR was indicated, (2) extreme risk or inoperability for conventional femoral artery, trans-apical, or trans-aortic access as determined by the institutional multi-disciplinary heart team, and (3) anatomic suitability for transcaval access according to a baseline CT scan analyzed by the NHLBI core laboratory. These are further detailed in the Online Appendix. Screening details on ineligible candidates were not collected.
The US Food and Drug Administration granted Investigational Device Exemption for this sponsor-investigator study, which had Institutional Research Boards approval from all 20 participating sites and NHLBI. All subjects consented in writing. The NHLBI Data Safety Monitoring Board provided oversight, and pre-specified endpoints were independently adjudicated by Medstar Heart and Vascular Institute Clinical Events Committee. Sites received on-site proctorship by the principal investigator and/or sponsor.
The IDE was sponsored by the senior author on behalf of NHLBI, which was the data coordination center. Sites participated without NHLBI funding. The manufacturer of the IDE test article (Amplatzer nitinol occluder devices, St Jude Medical) allowed FDA to crossreference the device master file for the IDE but did not otherwise participate in the study. Subjects were concurrently enrolled into the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies (TVT) registry (10) .
Technique of transcaval access and closure
The technique has been detailed previously (8, 9) . Briefly, the procedure is planned from the baseline TAVR CT (11, 12) to identify a calcium-free target on the right aortic wall that allows safe passage of the TAVR sheath from the inferior vena cava to the abdominal aorta. The trajectory of the sheath should be free of interposed obstacles (bowel) and the area of aortic entry should be away from important arterial branches allowing for provisional covered stent bailout if necessary. After heparin anticoagulation, a loop snare was placed in the aorta to serve as a target. A coaxial crossing system consisting of a 0.014″x300cm coronary guidewire (Confienza Pro 12 or Astato XS20, Asahi, Abbott) inside a 0.035″x145cm locking wire convertor (Piggyback, Vascular Solutions), inside a braided 0.035″x90cm microcatheter, inside a 6-7Fr renal-length IMA or RDC1 guiding catheter (Figure 3 ), was positioned into the cava, aimed towards the aortic snare, and electrified using a monopolar electrosurgery pencil at 50W during brief guidewire advancement across vascular walls. Once the 0.014″ guidewire was snared, counter-traction allowed the wire convertor and 0.035″ microcatheter to be advanced successively across the aortic wall and then exchanged for a rigid 0.035″x260cm guidewire (Lunderquist, Cook). The TAVR introducer sheath -Retroflex 3 or eSheath(13) (Edwards Lifesciences, Irvine CA) or extralarge Check-Flo (Cook, Bloomington IN) for Edwards Sapien valves, or large Check-Flo 18Fr × 40cm (Cook) for Medtronic Corevalve -was then introduced from the femoral vein into the aortic lumen over the rigid guidewire. Predilatation with a non-compliant coronary dilatation balloon (2-3mm × 20cm) was performed when necessary to advance the microcatheter. Retrograde TAVR was performed using standard transfemoral technique.
To close the access port after TAVR, heparin anticoagulation was fully reversed with protamine, and a nitinol cardiac occluder (Amplatzer Duct Occluder or Amplatzer Ventricular Septal Defect Occluder, St Jude Medical) was positioned in the aorta through the TAVR introducer sheath alongside a 0.014″ buddy guidewire, rotated sideways using a deflectable catheter (Agilis NxT SML curl, St Jude Medical), and deployed along the right aortic wall. Pigtail aortic angiography guided occluder device positioning. Aortocaval fistulas were accepted unless they caused heart failure from shunting. If retroperitoneal bleeding was evident, adjunctive balloon aortic tamponade or self-expanding covered stents (typically iliac limb extenders, Endologix or Trivascular, Irvine, CA) were deployed at physician discretion. Post-procedure antiplatelet and anticoagulation medications were administered according to local routine.
Data analysis
Clinical outcomes were entered into electronic case report forms and independently monitored. Follow-up CT scans, contrast enhanced when renal function permitted, were obtained before discharge and at 30 days. Angiograms and CT scans were analyzed in central NHLBI core laboratories. An independent clinical events adjudication committee classified all deaths, bleeding, vascular complication, major adverse cardiovascular events and their relatedness to transcaval access and closure according to a modification of VARC-2 (14) (Online Appendix). NHLBI has custody of all data; the sponsor and the principal investigator are responsible for data integrity.
The primary endpoint was device success, defined as successful transcaval access and deployment of a closure device without death or emergency open abdominal surgery. Data are reported as mean ± standard deviation or median (25 tht , 75 th percentile) as appropriate. Continuous and integer data were compared using a Student t test or Fisher exact test, respectively. To identify predictors of bleeding or vascular complications, we assessed association separately for each potential predictor (age, sex, closure device/sheath ratio, sheath aorta ratio, aortic diameter, fistula patency, balloon aortic tamponade, covered stent, transcaval procedure volume) and each discrete outcome by fitting a proportional-odds cumulative-logit model in SAS 9.4 (Cary, NC). Multivariable models were formed using a backwards stepwise selection of clinical and procedural factors (excluding those thought to be consequents of bleeding) until only factors with p<0.20 remained. Effects of transcaval experience were assessed by creating a dichotomous variable indicating the two highestenrolling sites.
Results
Enrollment 100 subjects enrolled and underwent attempted transcaval TAVR at 17 of 20 sites between July 2014 and June 2016. 30-day follow-up data were obtained for all. Sites performed a median of 2 (0,4) transcaval procedures before this study was initiated.
Procedure Outcomes
Transcaval access and closure was successful in 99/100 attempts. A typical procedure is depicted in Figure 4 . Baseline characteristics, including predictors of transthoracic access complications, are shown in Table 1 . Procedure characteristics are shown in Table 2 . In one subject the guidewire failed to cross, and the operator subsequently performed transfemoral artery TAVR complicated by iliac artery rupture. Device success, the primary endpoint of the study, was 98/100. This includes the failure to cross and another in whom the operator chose primary closure using a covered aortic stent instead of repositioning a fully-withdrawn nitinol occluder. All patients survived the immediate TAVR procedure, and none died as a direct consequence of transcaval access and closure, nor did any undergo emergency surgical rescue of the transcaval access site. Important TAVR complications included one case of THV-related coronary obstruction that was ultimately fatal, one case of aortic annular hematoma managed conservatively and successfully, no THV embolization, 16 new permanent pacemakers, and no case of endocarditis during the 30-day landmark analysis.
Inpatient and one-month follow-up data are shown in Table 3 . Four patients died before hospital discharge, two each of cardiovascular and non-cardiovascular causes. 30-day landmark survival was 92%. Seven deaths were adjudicated as cardiovascular, and one as non-cardiovascular. Specific causes of death are elaborated in the Online Appendix.
Bleeding and vascular complications are summarized in Table 4 . Transcaval-related bleeding was adjudicated as VARC2 major or life-threatening in 12/99. Overall 35 patients received a median of 2.0 (2.0, 4.0) units of red cell transfusions during their transcaval TAVR admission. Transcaval-related vascular complications were adjudicated as modified VARC2 major in 13/99, typically because of a retroperitoneal hematoma detected on mandatory CT scan combined with hemoglobin drop. Covered stents were placed in 8 subjects after transcaval access and closure, all but one during the same procedure. The indication was ongoing extravasation after deploying the transcaval closure device in the one patient who was receiving apixaban during the procedure, intolerable left-to-right shunt in two patients manifest as hemodynamic instability and deterioration in right ventricular function, and one used for primary closure of the transcaval access site after complete withdrawal of the nitinol occluder device. The indications for covered stent placement were less clear in the remaining four subjects: one had aortic root hematoma and the operator placed a covered aortic stent to reduce diagnostic ambiguity should hemodynamic instability ensue; one had unexplained hypotension not improved by covered stent that in retrospect was attributable to anesthesia medications; one was taken back to the cath lab in the evening after the transcaval procedure for hypotension and evident retroperitoneal hematoma, and a covered stent was placed out of caution even though there was no extravasation; and one in whom the operator planned a covered stent to treat a preexisting aortic dissection at the transcaval access site. Post-hoc multivariate analysis of clinical and procedural characteristics identified predictors of bleeding (Online Appendix), including small closure device/sheath diameter ratio, baseline hemodialysis, older age, larger aortas, and lower-enrolling sites. Post-hoc predictors of vascular complications included larger sheath/aorta diameter ratio, and lower-enrolling sites. The aorto-caval fistula was occluded immediately after transcaval TAVR in 36/99 (36%). Among evaluable mandatory CT scans (Table 5) , the fistula was occluded in 38/72 (53%) upon hospital discharge and 48/66 (72%) at 30-days. Incorporating angiography, 64/99 (64%) of tracts were occluded by 30 days.
Retroperitoneal hematoma (Table 5 ) was found by the core lab in 24% of subjects before discharge, and in 5% of subjects after 30 days. Most were graded small or moderate. There were no vascular complications after discharge.
No patient had a complication related to the transcaval closure device or closure site, nor aortic pseudoaneurysm, after hospital discharge.
There were two TAVR-related myocardial infarctions, one of which was fatal. There were five TAVR-related ischemic strokes. Three patients developed acute tubular necrosis classified as acute kidney index (AKI) scores of 3, including two who required hemodialysis. There were no cases of hemolytic anemia, nor of infected nitinol occluder device. Five had nadir platelet counts < 50×10 9 /mL, four of whom had a patent aortocaval fistula on the final angiogram, and none of whom had evident sequelae.
There were fewer complications in the half of patients treated at centers with more transcaval experience, including VARC-2 30-day safety events (17% vs 36%, p=0.03), covered stents (6% vs 11%, p=0.32), major or life-threatening bleeding (13% vs 28%, p=0.01), major vascular complications (11% vs 28%, p=0.03), and AKI≥1 (7% vs 15%, p=0.22), although some differences did not meet statistical significance. There was no difference in outcomes between the first and second half of patients enrolled.
Discussion
Transcaval access and closure for TAVR was successful in a cohort of patients without good conventional access options. This is remarkable given that most participating centers had limited prior transcaval experience, that we employed a permeable closure device, and that the patients had extensive comorbidity. The observed 30-day mortality was 8%, although no patient died or required surgical bailout as a direct consequence of transcaval access. Adjudicated bleeding and vascular complications were common. From a patient-centered outcome perspective, the primary observed morbidity, of blood transfusions, compares favorably to the morbidity of surgical transthoracic access.
The included patients were not eligible for femoral artery access and were deemed poorlysuited or ineligible for transthoracic access. 77% received contemporary low-profile THV devices. Eligibility for transthoracic access was a subjective clinical determination made by the local multidisciplinary heart team including cardiac surgeons. The included patients had high STS predicted risk of mortality (9.7 ± 6.3%) and a heavy burden of co-morbidities. We speculate that patients with fewer co-morbidities, who might be suitable for transthoracic access, might suffer fewer complications from transcaval access.
Despite fears of catastrophic hemorrhage, transcaval access appears well tolerated. We infer that the retroperitoneal space surrounding the aortic entry site pressurizes during and after closure, and that aortic bleeding decompresses into the nearby venous hole because retroperitoneal pressure exceeds venous pressure (Figure 2) . In a small number of patients, a transiently unrepaired aorto-caval fistula was well tolerated after pull-through of a closure device (Figure 5 ), or during replacement of the introducer sheath or dilator. Even after device closure, asymptomatic residual aorto-caval fistulae persisted in two-thirds before discharge and one-third after the first month.
Life-threatening (also known as "disabling") bleeding occurred in 12% of high or prohibitive risk patients after transcaval TAVR in this study (mean STS score 9.6), compared with 22.6% of intermediate-risk patients after transthoracic TAVR and 6.7% after transfemoral TAVR using the Sapien 3 THV in PARTNER-II (mean STS score 5.8)(6). In the other major pivotal TAVR trials for which data are available according to type of access, non-transfemoral access (transapical or transaortic) was associated with major vascular complication rates of 3.8-5.9% and life-threatening or major bleeding rates of 8.7-22.6% (3, 6, 15) . In large non-adjudicated single center and national TAVR registries, the rate of life-threatening and major bleeding with non-transfemoral access ranges from 3.6-37.3%, the rate of transfusion ranges from 8.9-25.4% and the rate of major vascular complications ranges from 0.6-2.4% (16) (17) (18) (19) (20) (21) .
Despite a paucity of randomized data on alternate extra-thoracic access such as trans-carotid, subclavian or trans-axillary, single center experience suggests these approaches compare favorably to transthoracic, with acceptable rates of bleeding and vascular access complications (17, 22, 23) . None of these had systematic follow-up imaging or independent adjudication. Compared with carotid, subclavian, and axillary artery access, transcaval access may provide: (1) superior operator ergonomics, in that the operators work from the standard right groin puncture site; (2) less tortuous sheath trajectory; (3) less risk of brachial plexus injury; (4) no surgical dissection. That said, all of these extra-thoracic access methods appear to work well.
In this study, adjudicators classified transcaval-related vascular and bleeding complications according to modified VARC-2 standards (14). Because we obtained CT scans systematically before discharge, and because blood transfusions were common (35%), VARC-2 classified vascular complications as "major" even when patients had otherwise uneventful clinical courses. For example, a patient who had a small retroperitoneal blood collection on CT and who had a 2 unit blood transfusion without "an overt source of bleeding" would be classified as having major bleeding, yet would have been classified as having no bleeding had there not been systematic follow-up imaging.
Covered stents were employed in 8% of subjects, fewer than half for extravasation or intolerable shunt through the permeable nitinol occluder devices, and none for catastrophic aortic disruption or hemodynamic collapse. Covered stents are considered a "failure" only because this study was designed to evaluate the specific permeable nitinol cardiac occluder devices in the closure of transcaval access ports. By contrast, in clinical practice a provisional strategy of nitinol occluder implantation and bail-out covered stenting seems prudent and practical.
Outcomes after transcaval access have improved since the first human experience (8) . Bleeding and vascular complications have declined because of technique refinements such as complete reversal of heparin anticoagulation before closure, consistent implantation of slightly oversized closure devices, use of a deflectable sheath to rotate the closure device horizontally during deployment, and liberal use of balloon aortic tamponade, even though the closure devices have not changed. In this prospective trial, centers with more transcaval experience trended toward fewer complications. Outcomes may improve further using a purpose-built closure device that is immediately hemostatic.
Limitations of this investigation include the absence of a control group, the inclusion of patients without other good options who have expected high morbidity and mortality not necessarily reflected in their risk score, the employment of a permeable nitinol occlude device, the participation of sites with little or no prior experience, the large proportion (18%) of missing follow-up CT, and limited data collection including cost, quality of life, and frailty. Some countervailing strengths include independent clinical event adjudication and data monitoring, and careful centralized analysis of follow-up CT. Compared with femoral artery access, transcaval procedures impart additional logistical complexity of planning, crossing, and closure. The extra expense of closure devices may possibly be offset by reduced morbidity and length of stay compared with transthoracic access.
Transcaval access may prove valuable for other clinical applications. It has been employed successfully as part of thoracic endovascular aneurysm repair (24) and to introduce 5.0 L percutaneous left ventricular assist devices (Impella, Abiomed) (25) . The transcaval approach may allow transcatheter implantation of other large devices, for example to treat aortic regurgitation.
Conclusion
Transcaval access is a realistic alternative for TAVR. These data support cautious clinical adoption in patients without good access options, and comparison against more established alternative access routes in lower risk patients. Outcomes and applicability might improve with more experience and using a purpose-built, impermeable closure device to achieve immediate hemostasis.
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Second valve academic research consortium Figure 2 . Proposed mechanism of hemodynamic stability after transcaval access using permeable nitinol occluder devices
Higher pressure in the relatively confined retroperitoneal space exceeds venous pressure (Inset) and causes aortic blood to return to the venous circulation through a nearby hole in the IVC (inset). The result is aortocaval fistula rather than hemodynamic collapse. Courtesy of A Hoofring, NIH Medical Arts Branch. * All TAVR procedures were successful, however 1/100 was performed via a femoral artery route, complicated by iliac artery rupture.
